StreetInsider.com News Articles

Vyome Holdings names Jerry Leonard as CFO, effective Sept. 1

Mon, 14 Sep 2026 08:01:23 -0400

Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biopharmaceutical company, has appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026. Leonard succeeds Robert Dickey IV, who had served as Interim CFO since August 2025.

Leonard brings more than 25 years of experience in financial management, SEC reporting, and corporate governance. He is the founder and CEO of ClearBridgeCFO, a financial leadership firm. He previously served as CFO and Secretary of VSee Health following its 2024 business combination, and held CFO roles at iDoc Virtual Telehealth Solutions and VSee Lab.

Earlier in his career, Leonard spent more than a decade as Vice

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Mon, 14 Sep 2026 08:00:00 -0400

Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, today announced the appointment of senior financial executive Jerry Leonard, CPA, MBA, as Chief Financial Officer. Mr. Leonard has assumed the role from September 1st, 2026 and will oversee the Company’s financial operations, financial reporting, accounting, internal controls, and related corporate governance responsibilities. Mr. Leonard succeeds Robert

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Mon, 14 Sep 2026 08:00:00 -0400

Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Chardan Starts Vyome Holdings (HIND) at Buy

Thu, 03 Sep 2026 05:10:15 -0400

Chardan analyst Keay Nakae initiates coverage on Vyome Holdings (NASDAQ: HIND) with a Buy rating and a price target of $3.50.

For an analyst ratings summary and ratings history on Vyome Holdings click here. For more ratings news on Vyome Holdings click here.

Shares of Vyome Holdings closed at $2.18 yesterday.

Form 8-K Vyome Holdings, Inc For: Aug 25

Fri, 28 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260828/26998528.html

Form 8-K Vyome Holdings, Inc For: Aug 25

Fri, 28 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260828/26998528.html

Form 8-K Vyome Holdings, Inc For: Aug 25

Tue, 25 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26974681.html

Form 8-K Vyome Holdings, Inc For: Aug 25

Tue, 25 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26974681.html

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet